Respiratory syncytial virus infections in children with acute myeloid leukemia: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 51, Issue 6, 2008, Pages 784-786

  Sung, Lillian ^a   Alonzo, Todd A ^b,c   Gerbing, Robert B ^b   Aplenc, Richard ^d   Lange, Beverly J ^d   Woods, William G ^e   Feusner, James ^f   Franklin, Janet ^c   Patterson, Maria J ^g   Gamis, Alan S ^h  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e EMORY UNIVERSITY   (United States)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Acute myeloid leukemia; Children; Respiratory syncytial virus

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INTERLEUKIN 2; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHILD; CHILDHOOD LEUKEMIA; CHILDHOOD MORTALITY; FEMALE; HUMAN; IMMUNOMODULATION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; VIRUS INFECTION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; PREVALENCE; PROGNOSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 56749151167     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21710     Document Type: Article

References (11)

1. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-1216. PMID: 9794957
2. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children's Cancer Group phase 3 trial for untreated pediatric acute myeloid leukemia (AML). Blood 2007;111:1044-1053.
3. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996;87:4979-4989.
4. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62.
5. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998;17:110-115.
6. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. [see comment]. J Pediatr 2003;143:532-540.
7. Anonymous. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. [see comment][comment]. Pediatrics 1998;102:531-537.
8. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-99.
9. Simoes EA, Sondheimer HM, Top FH, Jr., et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133:492-499. PMID: 8989345
10. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.[see comment]. N Engl J Med 1993;329:1524-1530.
11. Fuller H, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev 2006; Oct. 18;(4):CD004883. PMID: 1754220